What insurance policy changes affect code G93.32?

There are 2 tracked policy changes affecting code G93.32, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G93.32?

Payers that have issued tracked updates for code G93.32 include: Aetna.

How do I get notified when code G93.32 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G93.32. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G93.32?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

G93.32 Insurance Policy Changes

ICD-10 G93.32 is officially defined as "Myalgic encephalomyelitis/chronic fatigue syndrome." code G93.32 is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G93.32 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Aetna · Identified Aug 15, 2026Medium impact
Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)
Aetna covers alternative medicine interventions when they are supported by adequate evidence of safety and effectiveness in the peer-reviewed published medical literature, subject to benefit plan limitations and exclusions. Acupuncture, biofeedback, chelation therapy, chiropractic services and electrical stimulation are addressed under separate Aetna policies. Many other interventions are listed as experimental, investigational or unproven, including intravenous micronutrient therapy (Myers' Cocktail), Gua Sha, colon hydrotherapy and the Patricia Kane protocol, and standard benefit plans exclude nutritional supplements and medical marijuana.
Aetna · Identified Aug 15, 2026Medium impact
Myalgic Encephalomyelitis - Chronic Fatigue Syndrome (ME/CSF) (CPB 0369, reviewed 2026-05-20)
Aetna considers a set of exclusionary tests medically necessary for evaluating members suspected of having chronic fatigue syndrome (CFS), with the selection depending on the case. These include ANA, blood and serum chemistries, CBC with differential, ESR, HIV serology, liver function tests, thyroid function tests, urinalysis, and MRI of the head to rule out multiple sclerosis. Aetna considers many other laboratory tests, procedures and treatments experimental, investigational or unproven for CFS, including cytokine assays, gene expression profiling, metabolomics, ondansetron, duloxetine, rituximab and Anakinra.

Watch G93.32

Get one email when a payer policy names G93.32, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)

Myalgic Encephalomyelitis - Chronic Fatigue Syndrome (ME/CSF) (CPB 0369, reviewed 2026-05-20)

What insurance policy changes affect code G93.32?

Which payers have updated policy for code G93.32?

How do I get notified when code G93.32 policy changes?

Why do payers change policies for code G93.32?